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ABSTRACT  
Objectives 
Chlamydia prevalence in the general population is a potential outcome measure for the 
evaluation of chlamydia control programmes. We carried out a pilot study to determine the 
feasibility of using a postal survey for population-based chlamydia prevalence monitoring. 
Methods 
Postal invitations were sent to a random sample of 2,000 17-18 year-old women registered 
with a general practitioner in two pilot areas in England. Recipients were randomised to 
receive either a self-sampling kit (n=1,000), a self-sampling kit and offer of £5 voucher on 
return of sample (n=500), or a self-sampling kit on request (n=500). Participants returned a 
questionnaire and self-taken vulvovaginal swab sample for unlinked anonymous Chlamydia 
trachomatis testing. Non-responders were sent a reminder letter three weeks after initial 
invitation. We calculated the participation rate (number of samples returned/number of 
invitations sent) and cost per sample returned (including cost of consumables and postage) 
in each group.  
Results: A total of 155/2,000 (7.8%) samples were returned with consent for testing. 
Participation rates varied by invitation group: 7.8% in the group who were provided with a 
self-sampling kit, 14% in the group who were also offered a voucher and 1.0% in the group 
who were not sent a kit. The cost per sample received was lowest (£36) in the group who 
were offered both a kit and a voucher. 
Conclusions: The piloted survey methodology achieved low participation rates. This 
approach is not suitable for population-based monitoring of chlamydia prevalence among 
young women in England.  
Registration: UKCRN ID: 10913 
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KEY MESSAGES 
 We investigated the feasibility of using a postal survey with anonymous testing for 
population-based chlamydia prevalence monitoring in two pilot areas in England.  
 17-18 year-old women were either sent a self-sampling kit, sent a kit and offered a £5 
voucher or asked to request a kit. 
 The piloted survey methodology achieved low participation rates. Participation was 
highest in the group offered a £5 voucher to provide a specimen (14%).  
 Due to potential for selection bias and high costs of delivery, surveys of chlamydia 
prevalence using postal invitations are not suitable for population-based monitoring of 
chlamydia prevalence among young women in England.   
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INTRODUCTION 
Chlamydia trachomatis (‘chlamydia’) is a common bacterial sexually transmitted infection. 
The National Chlamydia Screening Programme (NCSP) was introduced in England in 2003 
and aims to control chlamydia and reduce the sequelae of infection through opportunistic 
screening of sexually active under 25-year olds. The majority of chlamydia infections are 
asymptomatic, with potential of serious complications if left untreated.[1] 
 
Routine monitoring of population prevalence of chlamydia would provide an important 
indicator of success of chlamydia control programmes, but presents a substantial challenge. 
The percentage testing positive measured using routinely-collected data from populations 
accessing testing cannot be extrapolated to the general population as individuals tested for 
chlamydia tend to have different risks of infection than those who have not been tested[2] 
and symptomatic patients are likely overrepresented. Previous studies have measured 
chlamydia prevalence among young adults in the general population[2], but their estimates 
are of limited use for monitoring changes in the levels of infection in relation to chlamydia 
screening as timely and regularly repeated measurements of chlamydia prevalence are 
needed. 
 
Between June and August 2011, we piloted a survey methodology to recruit and test young 
women for chlamydia. Our aim was to determine whether repeat cross-sectional surveys 
using postal invitations and anonymous testing (i.e. without return of test result) could be a 
feasible method of population-based chlamydia prevalence monitoring in England.  
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METHODS 
Selection and recruitment  
The pilot was carried out in two Primary Care Trusts (PCTs, local health administrations at 
the time of the study) in England. Eligible participants were identified using lists of patients 
registered with general practices (GPs). Women aged 17 to 18 years old were eligible. This 
age group was selected to maximise the expected proportion sexually active[3] and 
prevalence of infection[3] as well as the reliability of address data, given that the proportion 
of young adults living with their parents declines steeply with age over 16 years[4]. Only 18 
year-old women were included in one of the two PCTs in order to comply with local guidance 
about research involving children. The pilot study was limited to women as the most serious 
complications of chlamydia such as PID, ectopic pregnancy and infertility occur in women, 
thus making prevalence monitoring in women a higher priority.  
 
One thousand women were randomly selected from each PCT (from 7,544 eligible 
participants). The sample size was sufficient to identify a minimum 5% difference in 
response rate between three different types of postal invitation. The selected women were 
randomly allocated into three groups (Table 1). Group A were sent a self-sampling kit, 
consisting of an information leaflet, a short questionnaire including questions on sexual 
behaviour and ticked consent (to retain anonymity) for anonymous testing of their sample, a 
vulvovaginal swab to self-sample at home and a pre-paid return envelope (n=1,000). Group 
B were sent a self-sampling kit and also offered a £5 voucher on return of sample (n=500). 
Group C were invited to contact the study team by text message, email or return of postcard 
to obtain a self-sampling kit (n=500). All invitations included details of where they could be 
screened at a local clinical service. A reminder letter was sent to non-responders three 
weeks after the initial invitation. Individuals who did not wish to participate were asked to 
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complete and return a pre-paid postcard to the research team, indicating the reason they 
did not want to participate. 
 
Biological sample 
Participants returned the self-taken vulvovaginal swab to the Health Protection Agency (now 
part of Public Health England) where they were anonymised and unlinked from all personal 
identifying information. Samples were stored cold (4°C) before being tested (in batches) for 
chlamydia using the APTIMA COMBO 2 (Gen-Probe, San Diego, CA) assay.  
 
Participation rates 
Participation rates (the number of samples returned with consent to test divided by the total 
number of invitations sent) and reported sexual behaviours were compared between 
invitation groups using a chi-square test. An area-level indicator of deprivation (the Index of 
Multiple Deprivation, IMD[5]) was assigned to all invited individuals using their postcode of 
residence. Ranked IMD scores were grouped into quintiles. The potential for participation 
bias in each group was investigated by comparing the profile of participants to that of the 
invited population in terms of IMD quintile of residence. 
 
Cost per sample received 
The costs per invitation and per sample received for each randomisation group were 
estimated. This cost was defined as the total of the unit costs of all consumables, postage, 
testing and vouchers where relevant, divided by the number of invitations sent or the 
number of samples returned with consent for testing. Staff and overhead costs were not 
included, as these were assumed to be equivalent for all recruitment methods. 
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Regulatory approvals 
The study was approved by North London Research Ethics Committee (ref:10/H0717/57). 
Research governance approval was obtained from the two participating PCTs. Ethics and 
research governance approvals were obtained on the basis of the study being categorised as 
study type ‘other’ on the Integrated Research Application System (the  system for applying 
for the permissions and approvals for health care research in the UK). Thus the study was 
not categorised as a clinical trial. We sought clarification from the Medicines and Healthcare 
Products Regulatory Agency (MHRA, the body responsible for approval of clinical trials of 
investigational medicinal products in the UK) about the status of this study. MHRA confirmed 
that they considered the study to be “a health survey with no therapeutic intervention” and 
did not therefore require MHRA approval (personal communication, MHRA). The study was 
registered on the UK Clinical Research Network (CRN) portfolio (UKCRN ref: 10913) but was 
not registered as a clinical trial. 
 
RESULTS 
A total of 155 samples were returned with consent, equivalent to a 7.8% participation rate 
overall (Table 1). Thiry-three (21%) of the samples were returned after receipt of a reminder 
letter. A further 30 invitations (1.5%) were returned as undelivered. Participation rates 
varied by invitation group, with the highest participation rate (14%) achieved in the group 
offered a voucher, and very few responses received from the group invited to request a 
sampling kit (Group C). This group was therefore excluded from further comparative 
analyses. All samples received were adequate for testing. Three samples tested positive for 
chlamydia (1 in Group A, 2 in Group B). 
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Table 1: Participation rates and reported sexual behaviour by randomisation group 
 
Randomisation Group 
Overall 
(n=2,000) 
A: Kit 
(n=1,000) 
B: Kit + voucher 
(n=500) 
p value 
(A v B)^ 
C: No kit 
(n=500) 
n % n %  n % N % 
Participation rates          
Primary Care Trust 1$ 47/500 9.4% 41/250 16% 0.005 2/250 0.8% 90/1,000 9.0% 
Primary Care Trust 2 31/500 6.2% 31/250 12% 0.004 3/250 1.2% 65/1,000 6.5% 
Overall 78/1,000 7.8% 72/500 14% <0.001 5/500 1.0% 155/2,000 7.8% 
          
Reported sexual behaviour among 
participants* 
         
Ever had sex 58/77 75% 58/72 81% 0.44 4/5 80% 120/154 78% 
More than 1 sexual partner in the 
past 12 months# 
19/58 33% 26/58 45% 0.18 1/4 25% 46/120 38% 
At least 1 new sexual partner in the 
past 12 months# 
38/58 66% 37/58 64% 0.85 1/4 25% 76/120 63% 
More than 1 sexual partner in the 
past 3 months#   
5/58 8.6% 7/58 12% 0.54 0/4 0% 12/120 10% 
At least 1 new sexual partner  in the 
past 3 months#  
23/58 40% 23/58 40% 1.00 0/4 0% 46/120 38% 
Condom used at last intercourse# 17/55 31% 18/57 32% 0.94 3/4 75% 38/116 33% 
$ Included women aged 18 years only, to comply with local guidance about research involving 
children. 
* Variations in denominators represent item non-response. Percentages are calculated among 
women who returned a swab for testing and who had non-missing responses on the variable of 
interest 
# Among those reporting at least 1 sexual partner by the time of participation. 
^Χ2 test 
 
 
A total of 48 women declined consent by returning the pre-paid postcard (3% of all women 
who did not return a sample). The most commonly cited reasons for non-participation were 
that women did not want to use the swab (19/48, 40%), did not have the time (12/48, 25%), 
were not sexually active (9/48, 19%) or were not interested in chlamydia (7/48, 15%). Two 
respondents (4%) indicated that they wanted to receive their results. 
 
A total of 78% participants were sexually-experienced in terms of reporting at least one 
sexual partner by the time they participated (Table 1).  There were no significant differences 
in reported sexual behaviour between participants in Groups A and B. In both groups, 
women living in less deprived areas were over-represented among participants compared to 
the invited population (Online supplementary Figure 1). The profile of IMD quintile of 
residence among participants in Group B was more similar to that seen in the invited 
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population than the distribution of participants by IMD quintile in Group A, suggesting less 
participation bias in the group offered a voucher.  
 
The cost per invitation/sample received was £3.00/£51 for group A, £3.10/£36 for Group B 
and £0.50/£93 for Group C. 
 
DISCUSSION 
Our pilot of a postal survey of young women with anonymous testing for chlamydia resulted 
in low participation rates. Offering a small financial incentive increased participation, and 
reduced the cost per sample received.  
 
The main strength of this pilot study was that invitations were randomly allocated into 
different groups to allow investigation of the response rates that could be expected given 
different approaches. The study was subject to limitations. Firstly, we could not determine 
whether non-response was due to the invitation having not reached the intended person. In 
a previous study of chlamydia screening using GP lists, 27% of 16 to 39 year-olds could not 
be contacted at their registered address[6]. Our participation rates probably include some 
instances of this, as well as non-response among recipients. Secondly, while there was some 
indication that offering a £5 voucher recruited a more representative population in terms of 
deprivation, the sample size in this pilot was insufficient to explore this in detail.  
 
Given the small number of PCTs included it is possible that participants would have been 
higher in other areas. However, PCTs were selected to vary by geographical area 
(London/non-London) and background levels of chlamydia screening and there is no reason 
to think rates would have been higher in other PCTs. It was not possible to determine 
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whether participation rates would have been higher if participants had been offered their 
results. As people who take part in named chlamydia testing are, on average, at higher risk of 
infection than the general population[7], participants were not provided with their test 
results to reduce potential non-response bias. Furthermore, the batch-testing used in the 
study meant that tests would not have met diagnostic standards of time between testing 
and result.[8] Only 2/48 individuals cited non-provision of results as a reason not to take part 
in the survey. Although this is a small sample and only indicative of potential reasons for 
non-participation in the overall population, this suggests that providing test results would 
not have led to substantially higher response rates. The low participation rates are also 
consistent with those reported in other recent studies of chlamydia screening using postal 
invitations where named testing was used. For example, Bracebridge et al reported a 
participation rate of 13.2% in women invited by post to take a chlamydia screening test[9] 
and in their trial of chlamydia screening using postal invitations to order a home-sampling kit 
via the internet, van den Broek et al found that <20% of women aged 16 to 29 years invited 
for testing ordered and returned a home-sampling kit.[10]   
 
In summary, this pilot study showed that cross-sectional studies of chlamydia prevalence 
using postal invitations with anonymous testing for chlamydia are not a suitable method for 
measuring chlamydia prevalence in the general population in England. Other methods for 
monitoring chlamydia infection are therefore required. 
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